BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
BioRestorative Therapies, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$1.60+0.06 (+3.90%)
Close on Oct 19, 2026
- Market cap
- $28.36M
- P/E (TTM)
- –
- Dividend yield
- –
BioRestorative Therapies statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Services-Misc Health & Allied Services, NEC companies for comparison
Valuation
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Market Cap | $40.77M | $1.07B |
| Enterprise Value | $37.17M | $1.35B |
| PS Ratio | 113.91 | 1.63 |
| PB Ratio | 13.47 | 3.19 |
| P/TBV Ratio | 16.22 | 4.88 |
Enterprise value
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| EV / Sales | 103.87 | 1.78 |
Income (trailing twelve months)
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Revenue | $357.87K | $543.94M |
| Gross Profit | $329.55K | $162.51M |
| Operating Income | -$14.23M | -$1.92M |
| Net Income | -$11.06M | -$1.32M |
| EBITDA | -$14.01M | -$29.24K |
| EPS (Diluted) | -$1.08 | -$0.02 |
Margins
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Gross Margin | 92.1% | 32.7% |
| Operating Margin | -3975.0% | -4.46% |
| Profit Margin | -3089.5% | -3.18% |
| EBITDA Margin | -3916.1% | 2.41% |
Returns
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Return on Equity (ROE) | -241.1% | 0.49% |
| Return on Assets (ROA) | -147.7% | -3.06% |
| Return on Capital Employed (ROCE) | -470.2% | -2.29% |
Growth
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -8.47% | 7.11% |
| Revenue Growth (3Y CAGR) | 44.3% | 10.9% |
| Revenue Growth (5Y CAGR) | 36.1% | 13.2% |
Balance sheet
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.59M | $47.58M |
| Net Cash (Debt) | $3.59M | $217.65K |
| Net Cash Per Share | $0.14 | $0.01 |
| Equity (Book Value) | $3.03M | $189.59M |
| Book Value Per Share | $0.12 | $3.32 |
| Tangible Book Value | $2.51M | $1.72M |
| Working Capital | $2.19M | $29.77M |
Financial position
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Current Ratio | 2.35 | 1.41 |
| Quick Ratio | 2.23 | 0.97 |
Cash flow (trailing twelve months)
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.82M | $1.28M |
Efficiency
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.83 |
| Revenue Per Employee | $25.56K | $218.24K |
| Profits Per Employee | -$789.76K | -$5.96K |
| Employee Count | 14 | 897 |
Dividends and yields
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Earnings Yield | -27.1% | -1.25% |
Shares
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Shares Outstanding | 25,478,200 | 58,609,450 |
| Shares Change (YoY) | 38.5% | 2.64% |
| Shares Change (QoQ) | 187.0% | 0.29% |
| Float | 22,590,600 | 34,865,600 |
| Shares Held by Insiders | 11.3% | 16.6% |
Scores
| Measure | BioRestorative Therapies | Industry median |
|---|---|---|
| Altman Z-Score | -46.24 | 1.98 |
| Piotroski F-Score | 2 | 5 |
Calculated by StockData from BioRestorative Therapies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.